Journal • Combination therapy
|
ERBB4 (erb-b2 receptor tyrosine kinase 4) • PRMT5 (Protein Arginine Methyltransferase 5)
|
HER-2 positive • EGFR overexpression
|
cisplatin • erlotinib • paclitaxel • Nerlynx (neratinib) • doxorubicin hydrochloride • Tukysa (tucatinib) • pemrametostat (GSK3326595)